Diabetes Care Drugs & Devices Market to Reach US$ 244.46 Billion by 2033 at 8.3% CAGR; North America Leads with 37% Share; Key Players Include Abbott, Novo Nordisk, Medtronic

The global Diabetes Care Drugs & Devices Market reached US$ 119.86 billion in 2024 and is expected to reach US$ 244.46 billion by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033. Market growth is driven by the rising global prevalence of diabetes, increasing awareness of disease management, and continuous advancements in pharmaceutical therapies and medical device technologies.

Diabetes care drugs and devices include a wide range of pharmaceutical treatments and medical tools designed to monitor, manage, and control blood glucose levels in patients with diabetes. Drug therapies help regulate blood sugar by improving insulin secretion, enhancing insulin sensitivity, or reducing glucose absorption, while devices such as glucose monitoring systems, insulin pens, pumps, and continuous glucose monitors support accurate tracking and efficient treatment delivery. These solutions play a critical role in preventing diabetes-related complications, including cardiovascular diseases, neuropathy, nephropathy, and retinopathy. Growing adoption of advanced digital health solutions, improved patient compliance, and expanding access to diabetes care are further strengthening the long-term growth outlook of the diabetes care drugs and devices market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/diabetes-care-drugs-and-devices-market?sai-v

The Diabetes Care Drugs & Devices Market refers to the global industry encompassing pharmaceutical therapies and medical devices used for the monitoring, management, and treatment of diabetes.

Key Developments
✅ January 2026: In North America, the adoption of next-generation continuous glucose monitoring systems increased, with enhanced sensor accuracy and longer wear times driving patient preference.

✅ December 2025: In Europe, integrated diabetes management platforms combining glucose monitoring data with telehealth services expanded in clinical practices to support remote care.

✅ November 2025: In Asia-Pacific, demand for affordable insulin delivery devices and smart insulin pens rose as access programs and insurance coverage improved.

✅ October 2025: In Latin America, healthcare providers increased use of hybrid closed-loop systems in outpatient endocrinology clinics to enhance glycemic control in Type 1 diabetes patients.

✅ September 2025: In the Middle East, public health initiatives emphasized early detection of prediabetes and lifestyle interventions supported by digital diabetes tools.

✅ August 2025: In Africa, pilot projects introduced low-cost self-monitoring blood glucose devices in rural clinics to improve diabetes care access.

Mergers & Acquisitions
✅ January 2026: In North America, a leading diabetes technology company acquired a wearable insulin delivery startup to broaden its portfolio of integrated care devices.

✅ December 2025: In Europe, a major pharmaceutical firm acquired a digital diabetes management software provider to enhance data connectivity between drugs and devices.

✅ November 2025: In Asia-Pacific, a regional healthcare group acquired a distributor of advanced insulin pumps to expand access in emerging markets.

Key Players
F. Hoffmann-La Roche Ltd | Abbott Laboratories | Medtronic plc | Novo Nordisk A/S | Eli Lilly and Company | Merck & Co., Inc. | Terumo Corporation | B. Braun SE | Boehringer Ingelheim Pharmaceuticals, Inc. | Insulet Corporation

Key Highlights
Abbott Laboratories - Holds 18.9% share, driven by strong global adoption of continuous glucose monitoring systems, extensive product portfolio, and leadership in digital diabetes management solutions.

Novo Nordisk A/S - Holds 16.7% share, supported by market leadership in insulin and GLP-1 therapies, strong innovation pipeline, and expanding access in emerging markets.

Medtronic plc - Holds 14.3% share, benefiting from advanced insulin pump systems, integrated CGM technologies, and strong presence in automated insulin delivery solutions.

F. Hoffmann-La Roche Ltd - Holds 11.8% share, driven by established blood glucose monitoring brands, strong diagnostic expertise, and broad global distribution networks.

Eli Lilly and Company - Holds 10.2% share, supported by rapid growth in diabetes drug sales, particularly GLP-1 receptor agonists, and strong R&D capabilities.

Merck & Co., Inc. - Holds 7.4% share, leveraging oral diabetes therapies, strategic partnerships, and consistent demand across developed and developing regions.

Terumo Corporation - Holds 6.1% share, driven by strong demand for insulin delivery devices, syringes, and pen needles, particularly in Asia-Pacific markets.

B. Braun SE - Holds 5.3% share, benefiting from expertise in diabetes infusion devices, consumables, and hospital-based diabetes care solutions.

Insulet Corporation - Holds 5.0% share, supported by growing adoption of tubeless insulin pump systems and expanding patient base in homecare settings.

Boehringer Ingelheim Pharmaceuticals, Inc. - Holds 4.3% share, driven by oral antidiabetic medications and collaborative drug development initiatives.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=diabetes-care-drugs-and-devices-market?sai-v

Market Drivers
- Rising global prevalence of diabetes increasing long-term demand for drug therapies and monitoring devices.

- Growing adoption of continuous glucose monitoring systems and insulin delivery devices.

- Increasing awareness of early diagnosis, glycemic control, and diabetes management.

- Technological advancements in insulin formulations, smart insulin pens, and digital diabetes platforms.

- Expansion of healthcare access and diabetes care programs across emerging and developed markets.

Industry Developments
- Continuous innovation in insulin analogs, oral antidiabetic drugs, and combination therapies.

- Rising adoption of digital and connected diabetes care devices integrated with mobile health platforms.

- Strategic collaborations between pharmaceutical companies and medical device manufacturers.

- Expansion of manufacturing and distribution capabilities to meet growing global patient needs.

- Regulatory approvals supporting new diabetes drugs and advanced glucose monitoring technologies.

Regional Insights
North America - 37% share: "Driven by high diabetes prevalence, advanced healthcare infrastructure, strong reimbursement systems, and widespread adoption of innovative diabetes management technologies."

Europe - 26% share: "Supported by established diabetes care programs, increasing adoption of continuous glucose monitoring, and strong regulatory oversight."

Asia Pacific - 30% share: "Fueled by large diabetic population, rising healthcare awareness, expanding access to diabetes care devices, and growing investments in digital health."

Latin America - 4% share: "Driven by improving access to diabetes treatment, growing public health initiatives, and increasing adoption of glucose monitoring devices."

Middle East & Africa - 3% share: "Supported by rising diabetes incidence, healthcare infrastructure development, and expanding availability of diabetes care products."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/diabetes-care-drugs-and-devices-market?sai-v

Key Segments

By Product Type
Diabetes devices hold a significant share of the market, driven by widespread adoption of blood glucose monitoring systems, continuous glucose monitoring devices, and insulin delivery solutions. Diabetes drugs represent a major segment, supported by long-term pharmacological management of diabetes and continuous introduction of advanced therapeutic classes.

By Application
Type 2 diabetes dominates the application segment, driven by high global prevalence and long-term disease management needs. Type 1 diabetes holds a substantial share, supported by intensive insulin therapy and growing use of advanced monitoring devices. Gestational diabetes contributes notably due to increased screening during pregnancy. Prediabetes is emerging as a key segment, driven by rising awareness, early diagnosis, and preventive healthcare initiatives.

By End-User
Hospitals represent a major end-user segment, driven by inpatient care, diagnosis, and advanced treatment facilities. Specialty clinics hold a significant share, supported by focused diabetes management and endocrinology services. Homecare settings are growing rapidly, driven by increasing preference for self-monitoring and remote diabetes management. Diagnostic centers contribute steadily through screening and routine testing, while other end users support overall market expansion.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.